

Target : Anaeropharma Science Inc.

Outline : Biopharma company aiming to launch a new drug in cooperation with the pharmaceutical industry, with the Drug Delivery System (DDS) developed by Shinshu University as its core

Authorized investment : ¥4.2 billion (maximum)


Anaeropharma Science

Using Bifidobacteria to industrialize the technology for a Drug Delivery System (DDS) to deliver concentrated drug doses to affected areas


Dose of genetically engineered bifidobacteria administered. Bifidobacteria are anaerobic and prefer the characteristically low-oxygen environments found in solid cancer tissue

A dose of prodrugs is administered, which reacts with the enzymes in the bifidobacteria accumulated inside the cancer tissue, producing anti-cancer agents only in the affected area of solid cancer tissue

Boosts the effectiveness of anti-cancer agents while mitigating side-effects



Technology transfer



Joint development

Investment
Managerial support

Watervein Partners

Investment
Managerial support

Companies in related
industries

Investment

- Use Bifidobacteria based DDS as a development platform with the aim of meeting unmet medical needs
- Through joint support alongside private sector venture capital aim to generate domestic drug discovery success stories